为婴儿提供公平的呼吸道合胞病毒预防:全球实施的挑战与机遇
本文综述全球婴儿呼吸道合胞病毒(RSV)预防的挑战与机遇。Gavi批准RSV孕产妇疫苗接种规划,部分高收入国家已引入孕晚期疫苗或婴儿长效单克隆抗体,真实世界数据显示可大幅减少RSV下呼吸道疾病就医和住院;但97%的RSV相关死亡发生在中低收入国家,这些国家少有授权和引入预防策略。综述围绕疾病负担、疫苗与单克隆抗体研发、卫生经济学与影响模型、政策、实施与规划、监测和认知等关键领域,依据世界卫生组织《2030年免疫议程》和联合国「不让任何人掉队」框架,讨论资源受限地区扩大RSV预防可及性的挑战与机遇。
要点
- Gavi批准RSV孕产妇疫苗接种规划,公平可及取得进展但仍需后续工作。
- 孕晚期RSV融合蛋白prefusion构象疫苗或婴儿长效单克隆抗体真实世界有效。
- 97%的RSV相关死亡发生在中低收入国家,但少有国家授权和引入预防策略。
核心结论
- 综述总结RSV预防研究进展,强调需采取紧急步骤确保全球所有婴儿公平获得RSV预防。
研究设计与样本
- 本文为综述,依据世界卫生组织《2030年免疫议程》和联合国「不让任何人掉队」非歧视可持续发展框架,讨论资源受限地区扩大婴儿RSV预防可及性的挑战与机遇。
主要发现
- Gavi批准RSV孕产妇疫苗接种规划,标志着公平可及的重大进展,但仍有重要工作要做。
- 部分国家(多为高收入国家)已引入孕晚期RSV融合蛋白prefusion构象疫苗或婴儿长效单克隆抗体。
- 实施后真实世界有效性数据显示,两种策略均可大幅减少RSV下呼吸道疾病就医和住院。
- RSV对全球婴儿和脆弱儿童造成沉重负担,97%的相关死亡发生在中低收入国家。
- 中低收入国家中少有已授权和引入RSV预防策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The approval for a respiratory syncytial virus (RSV) maternal vaccination programme by Gavi, The Vaccine Alliance, marks substantial progress toward equitable access, with important work still to come. Several countries, most of which are high-income, have introduced RSV immunisation either using a vaccine containing the RSV fusion protein in its prefusion conformation, which is given to pregnant people in late pregnancy, or by using a long-acting monoclonal antibody (mAb) administered directly to infants. Post-implementation real-world effectiveness data show a major impact in reducing medically attended RSV-lower respiratory tract illness and hospitalisation using either strategy. Although RSV poses a substantial burden to infants and vulnerable children worldwide, 97% of associated mortality occurs in low-income and middle-income countries. However, few of these countries have authorised and introduced RSV preventive strategies. This Review outlines the challenges and opportunities for expanding access to RSV prevention for infants in resource-restricted settings guided by WHO's Immunization Agenda 2030 and the UN's Leave No One Behind framework for non-discriminatory sustainable development. We discuss burden, vaccine and mAb development, health economics and impact modelling, policy, implementation and programmatic considerations, surveillance, and awareness as key RSV domains. This Review summarises recent advances in research and highlights the urgent steps needed to ensure equitable access to RSV prevention for all infants worldwide.
引用
- Shaaban FL, Groenendijk RW, Baral R, et al. The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementation. Lancet Glob Health. 2025. PMID: 41197645. doi:10.1016/S2214-109X(25)00379-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。